The drug is used to treat and prevent bronchospasm in patients aged four years and older, including those with obstructive airway diseases, and to treat exercise-induced bronchospasm.
Also read: Second-best performing midcap stock of 2026 surges another 9% after strong parent resultsIn an exchange filing, the company said the product is expected to be launched in the United States in the first half of FY27. According to IQVIA data, the US market for albuterol inhalers is valued at around $1.5 billion.
Commenting on the development, Managing Director and Global CEO Achin Gupta said the approval “marks an important milestone for Cipla and reflects our strong scientific and regulatory capabilities in complex inhalation products.”He added that lung health remains a key focus area as Cipla looks to build a differentiated global portfolio.
Also read: L&T shares rise after buildings and factories vertical wins orders worth up to ₹2,500 crore
Marc Falkin, CEO of Cipla North America, said, “The product will be manufactured at our newly constructed, dedicated inhalation facility in Fall River, Massachusetts, reinforcing both supply resilience and our domestic manufacturing footprint.”
The company also plans to ramp up volume through which it expects to “drive meaningful difference in the lives of patients,” Falkin added.
Shares of the company jumped 4.75% to hit an intraday high of ₹1,295 before paring some gains. The stock was trading at ₹1,276 as of 10.33 am, still 3.21% above its previous closing price. It has declined 22.5% over the last six months.
